Preliminary results of SBRT treatment of pulmonary oligometastasis from head and neck tumors
Hua Yonghong1, Dong Ruizeng2, Piao Yongfeng1, Wang Lei1, Wang Qiong1, Tao Changjuan1, Chen Yuanyuan1, Chen Xiaozhong1, Hu Qiaoying1, Chen Ming1
1Institute of Cancer and Basic Medicine, Department of Radiation Oncology, Chinese Academy of Science, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China; 2Department of Cancer and Basic Medicine, Department of Surgery, Chinese Academy of Sciences, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou 310022, China
Abstract：Objective To preliminarily evaluate the efficacy and safety of stereotactic body radiotherapy (SBRT) for pulmonary oligometastatic tumors from head and neck carcinoma. Methods Clinical data of 24 patients with pulmonary oligometastasis from head and neck carcinoma undergoing SBRT in Zhejiang Cancer Hospital from January 2014 to May 2019 were retrospectively analyzed. Survival analysis was performed by Kaplan-Meier method. Results Among the 24 patients, 12 cases were diagnosed with nasopharyngeal origin and 12 cases of non-nasopharyngeal origin. A total of 34 pulmonary metastatic lesions were treated with SBRT. The median follow-up time was 19.5 months. Thirteen cases developed new lesions after SBRT, and 9 of them occurred within 1 year after SBRT treatment. The actual 1-year local control rate was 95%. The median progression-free survival was 15.2 months, and the 1-and 2-year progression-free survival were 59% and 46%, respectively. The 2-and 3-years overall survival rate at were 71% and 51% fter lung metastasis, respectively. Univariate analysis showed that the patients with primary lesions located in nasopharynx and disease-free interval of more than 1 year had survival advantage. No more than grade 3 radiation-induced injury was observed in the whole cohort after SBRT, and the incidence of mild radiation-induced injury was 13%. Conclusions SBRT is safe and effective in the treatment of pulmonary oligometastatsis from head and neck carcinoma, and it may be more effective for patients with primary tumors located in nasopharynx.
Hua Yonghong,Dong Ruizeng,Piao Yongfeng et al. Preliminary results of SBRT treatment of pulmonary oligometastasis from head and neck tumors[J]. Chinese Journal of Radiation Oncology, 2021, 30(3): 235-238.
[1] Hellman S,Weichselbaum RR.Oligometastases[J].J Clin Oncol,1995,13(1):8-10.DOI:10.1200/JCO.1995.13.1.8.
[2] Weichselbaum RR,Hellman S.Oligometastases revisited[J].Nat Rev Clin Oncol,2011,8(6):378-382.DOI:10.1038/nrclinonc.2011.44.
[3] Furuya M,Yonemitsu Y,Aoki I.Ⅲ.Angiogenesis:complexity of tumor vasculature and microenvironment[J].Curr Pharm Des,2009,15(16):1854-1867.DOI:10.2174/138161209788453275.
[4] Young ER,Diakos E,Khalid-Raja M,et al.Resection of subsequent pulmonary metastases from treated head and neck squamous cell carcinoma:systematic review and meta-analysis[J].Clin Otolaryngol,2015,40(3):208-218.DOI:10.1111/coa.12348.
[5] Pan CC,Wu PH,Yu JR,et al.Comparative survival analysis in patients with pulmonary metastases from nasopharyngeal carcinoma treated with radiofrequency ablation[J].Eur J Radiol,2012,81(4):e473-477.DOI:10.1016/j.ejrad.2011.05.037.
[6] 唐秋,胡巧英,朴永锋,等.不同方式治疗87例鼻咽癌放疗后肺寡转移患者的疗效分析[J].中华肿瘤杂志,2016,38(3):218-222.DOI:10.3760/cma.j.issn.0253-3766.2016.03.011.
Tang Q,Hu QY,Piao YF,et al.Analysis of the therapeutic effects of different treatment modalities on the outcomes of 87 patients with lung oligometastasis from nasopharyngeal carcinoma after radiotherapy[J].Chin J Oncol,2016,38(3):218-222.DOI:10.3760/cma.j.issn.0253-3766.2016.03.011.
[7] Chang JY,Senan S,Paul MA,et al.Stereotactic ablative radiotherapy versus lobectomy for operable stage Ⅰ non-small-cell lung cancer:a pooled analysis of two randomised trials[J].Lancet Oncol,2015,16(6):630-637.DOI:10.1016/S1470-2045(15)70168-3.
[8] Ball D,Mai GT,Vinod S,et al.Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL):a phase 3,open-label,randomised controlled trial[J].Lancet Oncol,2019,20(4):494-503.DOI:10.1016/S1470-2045(15)70168-3.
[9] Bonomo P,Greto D,Desideri I,et al.Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma:is the deferral of systemic therapy a potential goal?[J].Oral Oncol,2019,93(1):1-7.DOI:10.1016/j.oraloncology.2019.04.006.
[10] Ricco A,Davis J,Rate W,et al.Lung metastases treated with stereotactic body radiotherapy:the RSSearch?B patient Registry′s experience[J].Radiat Oncol,2017,12(1):35.DOI:10.1186/s13014-017-0773-4.
[11] Aoki M,Hatayama Y,Kawaguchi H,et al.Clinical outcome of stereotactic body radiotherapy for primary and oligometastatic lung tumors:a single institutional study with almost uniform dose with different five treatment schedules[J].Radiat Oncol,2016,11:5.DOI:10.1186/s13014-016-0581-2.
[12] Ahmed KA,Scott JG,Arrington JA,et al.Radiosensitivity of lung metastases by primary histology and implications for stereotactic body radiation therapy using the genomically adjusted radiation dose[J].J Thorac Oncol,2018,13(8):1121-1127.DOI:10.1016/j.jtho.2018.04.027.
2021, Vol. 30 
